INTRODUCTION AND OBJECTIVES: Infertility is a chronic disease which affects many couples worldwide. As fertility treatment is expensive in the US, adequate insurance coverage for both the man and woman is essential to minimize the financial burden of treatment. The aim of this study was to explore the evaluation, treatment, and insurance coverage related to male fertility treatment among infertile couples in the US.
METHODS: Data for this cross-sectional study was obtained from FertilityIQ.com, which is a national website that infertile couples may use to obtain information related to fertility treatment and reproductive centers in the US. We identified a cohort of infertile couples with male factor infertility and invited them to complete a survey related to sociodemographics, male fertility evaluation, treatment and costs related to the care they received. IRB approval was obtained.
RESULTS: The survey was sent to infertile couples with male factor infertility in April 2018 of which 572 completed the survey. The average age of the respondent was 35.4 with 42.9% reporting a college education. Overall, 96.3% had at least one abnormal semen parameter. Of all men, 71.5% were referred to a male fertility specialist with the majority being referred by the gynecologist of their female partner. Of the evaluated men, 70.4% underwent hormone testing and 29.2% were prescribed Clomid. For some couples, their insurance covered a majority of the initial evaluation of the male partner (e.g. 45.4% received >75% coverage), but fewer covered medications related to male factor (e.g. 57.8% received <25% coverage.). Varicocele repair was the most commonly performed surgical procedure to improve sperm production. Of the azoospermic men who required surgical sperm extraction (17.6%), TESE was most commonly performed procedure. Over 70% of men reported insurance coverage between 0-25%. Of the men that froze sperm for later use, 78.0% received 0-25% coverage.
CONCLUSIONS: Although this cohort includes couples with male factor infertility and abnormal semen parameters, 28% of the men were not evaluated by a male fertility specialist. In addition, insurance coverage for medication and surgical procedures related to male factor infertility were low. These findings may be of concern as insufficient coverage of the infertile man may lead to missed opportunities for identifying reversible causes of infertility/medical comorbidities and places an unfair burden on the female partner. METHODS: A systematic review and meta-analysis was conducted by searching the MEDLINE and EMBASE databases for relevant published studies in English language (1997e2017). Studies were eligible if they included the comparison of using fresh and frozen-thawed testicular sperm followed by ICSI. Two reviewers independently performed data extraction, quality assessment and assessed the risk of bias. The overall summary risk estimated the
